EXERTIS Scales With Boomi, Increasing Partner and Customer Satisfaction Globally
13.9.2023 11:00:00 EEST | Business Wire | Press release
Boomi™, the intelligent connectivity and automation leader, today announced that leading UK-based technology distributor EXERTIS is expanding its use of Boomi’s category-leading, unified integration platform to improve partner and customer satisfaction on a global scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230808691045/en/
EXERTIS Scales With Boomi, Increasing Partner and Customer Satisfaction Globally (Graphic: Business Wire)
EXERTIS works with 2,400 technology partners, including Apple, Samsung, Microsoft, and Dell Technologies, and serves more than 50,000 retailers and resellers in 20+ countries. As part of a full spectrum of services, EXERTIS supplies IT hardware and software to electronic retailers and hosts some clients’ ecommerce stores, managing their full, end-to-end customer journeys.
Prior to using Boomi, EXERTIS had grown through acquisition, where each of its operating entities possessed a mix of legacy and modern integration tools. As a result, manual custom coding; ageing, on-premises enterprise service bus (ESB) systems; and outdated electronic data interchange (EDI) tools and services were widespread and disconnected. This led to slow development and deployment of new integrations, high technical debt, and a declining pool of developers with specialised skills that stifled the scalability and flexibility EXERTIS needed.
With an acquisition strategy that benefitted from inter-company trade synergies, EXERTIS needed a future-proof solution. After evaluating various integration and EDI solutions, EXERTIS saw how Boomi could modernise its IT environment and support its growth and acquisition strategy through the platform’s low-code ease of use; speed of development; and multiple capabilities in a unified, multi-tenant, cloud-based solution.
Using its core integration, B2B/EDI management, and API management capabilities, the Boomi platform enables EXERTIS to connect into over 100 internal and third-party systems with 200 more systems in the pipeline, providing EXERTIS with the agility for further innovation.
“EXERTIS has its origins in venture capitalism and private equity, and a core part of our work centred around the integration of acquired entities,” said Tim Griffin, CEO, EXERTIS. “There are lots of solutions on the market, but I would put Boomi at the top, especially when you consider its multi-tenant architecture and cloud basis. Our developers became proficient in as little as three weeks, and we now have a shared development environment that promotes reuse of integrations across our business.”
In light of its early success, EXERTIS is expanding its use of Boomi to digitally transform its global environment for integration and EDI transactions, and improve partner and customer satisfaction on a global scale.
“We’re delighted to expand our engagement and support of EXERTIS as they continue to grow globally,” said Adrian Trickett, Vice President and General Manager, EMEA at Boomi. “By enabling frictionless transactions, EXERTIS has increased the percentage of orders from its partners and customers, and freed time for its people to pursue more value-adding work.”
Learn more about the EXERTIS use case with Boomi here.
Additional Resources
- Learn more about the Boomi platform
- Explore the Boomiverse Community
- Follow Boomi on Twitter, LinkedIn, Facebook, and YouTube
About Boomi
Boomi aims to make the world a better place by connecting everyone to everything, anywhere. The pioneer of cloud-based integration platform as a service (iPaaS), and now a category-leading, global software as a service (SaaS) company, Boomi touts the largest customer base among integration platform vendors and a worldwide network of approximately 800 partners – including Accenture, Capgemini, Deloitte, SAP, and Snowflake. Global organisations turn to Boomi’s award-winning platform to discover, manage, and orchestrate data, while connecting applications, processes, and people for better, faster outcomes. For more information, visit http://www.boomi.com.
© 2023 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230808691045/en/
Contact information
Media:
Kristen Walker
Global Corporate Communications
kristenwalker@boomi.com
+1-415-613-8320
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
